Skip to main content

Do Urine Drug Tests Reveal Substance Misuse Among Patients Prescribed Opioids for Chronic Pain?

Abstract

Background

Urine drug testing (UDT) is a recommended risk mitigation strategy for patients prescribed opioids for chronic pain, but evidence that UDT supports identification of substance misuse is limited.

Objective

Identify the prevalence of UDT results that may identify substance misuse, including diversion, among patients prescribed opioids for chronic pain.

Design

Retrospective cohort study.

Subjects

Patients (n=638) receiving opioids for chronic pain who had one or more UDTs, examining up to eight substances per sample, during a one 1-year period.

Main Measures

Experts adjudicated the clinical concern that UDT results suggest substance misuse or diversion as not concerning, uncertain, or concerning.

Key Results

Of 638 patients, 48% were female and 49% were over age 55 years. Patients had a median of three UDTs during the intervention year. We identified 37% of patients (235/638) with ≥1 concerning UDT and a further 35% (222/638) having ≥1 uncertain UDT. We found concerning UDTs due to non-detection of a prescribed substance in 24% (156/638) of patients and detection of a non-prescribed substance in 23% (147/638). Compared to patients over 65 years, those aged 18–34 years were more likely to have concerning UDT results with an adjusted odds ratio (AOR) of 4.8 (95% confidence interval [CI] 1.9–12.5). Patients with mental health diagnoses (AOR 1.6 [95% CI 1.1–2.3]) and substance use diagnoses (AOR 2.3 [95% CI 1.5–3.7]) were more likely to have a concerning UDT result.

Conclusions

Expert adjudication of UDT results identified clinical concern for substance misuse in 37% of patients receiving opioids for chronic pain. Further research is needed to determine if UDTs impact clinical practice or patient-related outcomes.

This is a preview of subscription content, access via your institution.

Figure 1

References

  1. 1.

    Guy GP, Jr., Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697-704.

    Article  Google Scholar 

  2. 2.

    Schieber LZ, Guy GP, Seth P, Losby JL. Variation in adult outpatient opioid prescription dispensing by age and sex - United States, 2008-2018. MMWR Morbidity and mortality weekly report. 2020;69(11):298-302.

    Article  Google Scholar 

  3. 3.

    Olfson M, Wang S, Wall MM, Blanco C. Trends in opioid prescribing and self-reported pain among US adults. Health Aff (Millwood). 2020;39(1):146-154.

    Article  Google Scholar 

  4. 4.

    Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162(4):276-286.

    Article  Google Scholar 

  5. 5.

    Dowell D, Haegerich TM, Chou R. Cdc guideline for prescribing opioids for chronic pain—united states, 2016. JAMA. 2016;315(15):1624-1645.

    CAS  Article  Google Scholar 

  6. 6.

    Jarvis M, Williams J, Hurford M, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 2017;11(3):163-173.

    Article  Google Scholar 

  7. 7.

    VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain. 2017; https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOTCPG022717.pdf. Accessed January 30, 2021.

  8. 8.

    Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152(11):712-720.

    Article  Google Scholar 

  9. 9.

    Nuckols TK, Anderson L, Popescu I, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160(1):38-47.

    Article  Google Scholar 

  10. 10.

    Reisfield GM, Bertholf R, Barkin RL, Webb F, Wilson G. Urine drug test interpretation: what do physicians know? J Opioid Manag. 2007;3(2):80-86.

    Article  Google Scholar 

  11. 11.

    Starrels JL, Fox AD, Kunins HV, Cunningham CO. They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med. 2012;27(11):1521-1527.

    Article  Google Scholar 

  12. 12.

    Argoff CE, Alford DP, Fudin J, et al. Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations. Pain Med. 2018;19(1):97-117.

    Article  Google Scholar 

  13. 13.

    Turner JA, Saunders K, Shortreed SM, et al. Chronic opioid therapy urine drug testing in primary care: prevalence and predictors of aberrant results. J Gen Intern Med. 2014;29(12):1663-1671.

    Article  Google Scholar 

  14. 14.

    Matteliano D, Chang YP. Describing prescription opioid adherence among individuals with chronic pain using urine drug testing. Pain management nursing : official journal of the American Society of Pain Management Nurses. 2015;16(1):51-59.

    Article  Google Scholar 

  15. 15.

    Michna E, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. The Clinical journal of pain. 2007;23(2):173-179.

    Article  Google Scholar 

  16. 16.

    Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46.

    Article  Google Scholar 

  17. 17.

    Liebschutz JM, Xuan Z, Shanahan CW, et al. Improving adherence to long-term opioid therapy guidelines to reduce opioid misuse in primary care: a cluster-randomized clinical trial. JAMA Intern Med. 2017;177(9):1265-1272.

    Article  Google Scholar 

  18. 18.

    Lasser KE, Shanahan C, Parker V, et al. A multicomponent intervention to improve primary care provider adherence to chronic opioid therapy guidelines and reduce opioid misuse: a cluster randomized controlled trial protocol. J Subst Abuse Treat. 2016;60:101-109.

    Article  Google Scholar 

  19. 19.

    Liebschutz JM, Lange AV, Heymann OD, et al. Communication between nurse care managers and patients who take opioids for chronic pain: strategies for exploring aberrant behavior. J Opioid Manag. 2018;14(3):191-202.

    Article  Google Scholar 

  20. 20.

    Rose AJ, Bernson D, Chui KKH, et al. Potentially inappropriate opioid prescribing, overdose, and mortality in Massachusetts, 2011-2015. J Gen Intern Med. 2018;33(9):1512-1519.

    Article  Google Scholar 

  21. 21.

    Liebschutz JM, Saitz R, Weiss RD, et al. Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. J Pain. 2010;11(11):1047-1055.

    Article  Google Scholar 

  22. 22.

    Volkow ND, McLellan AT. Opioid Abuse in chronic pain — misconceptions and mitigation strategies. New England Journal of Medicine. 2016;374(13):1253-1263.

    CAS  Article  Google Scholar 

  23. 23.

    National Center for Injury Prevention and Control. CDC compilation of benzodiazepines, muscle relaxants, stimulants, zolpidem, and opioid analgesics with oral morphine milligram equivalent conversion factors, 2019 version. 2019; Available at https://www.cdc.gov/drugoverdose/resources/data.html.

  24. 24.

    McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276-282.

    Article  Google Scholar 

  25. 25.

    Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183-188.

    Article  Google Scholar 

  26. 26.

    Chua I, Petrides AK, Schiff GD, et al. Provider misinterpretation, documentation, and follow-up of definitive urine drug testing results. J Gen Intern Med. 2020;35(1):283-290.

    Article  Google Scholar 

  27. 27.

    Merlin JS, Young SR, Starrels JL, et al. Managing concerning behaviors in patients prescribed opioids for chronic pain: a Delphi study. J Gen Intern Med. 2018;33(2):166-176.

    Article  Google Scholar 

  28. 28.

    U.S. Department of Health and Human Services. HHS guide for clinicians on the appropriate dosage reduction or discontinuation of long-term opioid analgesics. 2019; Available at: https://www.hhs.gov/opioids/sites/default/files/2019-10/Dosage_Reduction_Discontinuation.pdf. Accessed March 16, 2021.

  29. 29.

    Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med. 2019;380(24):2285-2287.

    Article  Google Scholar 

Download references

Funding

This study was funded by the National Institutes of Health/National Institute on Drug Abuse K23DA042168.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Marc R. Larochelle MD, MPH.

Ethics declarations

Conflict of Interest

Dr. Larochelle reports receiving consulting funds paid to his institution by OptumLabs for opioid use disorder research outside the scope of the submitted work. Dr. Krebs reports receiving travel paid by the law firm representing the state of Oklahoma for expert witness services in support of the state’s litigation against opioid manufacturers. Authors have no other conflicts of interest to report.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 64 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Larochelle, M.R., Cruz, R., Kosakowski, S. et al. Do Urine Drug Tests Reveal Substance Misuse Among Patients Prescribed Opioids for Chronic Pain?. J GEN INTERN MED (2021). https://doi.org/10.1007/s11606-021-07095-8

Download citation

KEY WORDS

  • urine drug tests
  • opioid analgesics
  • chronic pain